Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by BearDownAZon Apr 21, 2015 2:35pm

373 Views

Post# 23649728

DM on BNN Business Day tomorrow 4/22

https://www.resverlogix.com/blog/2015/04/21/resverlogix-featured-on-bnns-business-day-with-frances-horodelski/

Donald McCaffrey, President and CEO of Resverlogix will appear live on BNN’s Business Day with Frances Horodelski on April 22 at 10:15 am ET. Tune in to watch the live interview!

Here is a link to the show Business Day: https://www.bnn.ca/Shows/Business-Day.aspx

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale